Trial Profile
UNresectable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy. A Study to Evaluate the Efficacy and Safety of the Combined Use of Avelumab With Radiation Therapy for the Treatment of Unresectable Cutaneous Squamous Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms UNSCARRed
- 12 Apr 2019 Status changed from not yet recruiting to recruiting.
- 18 Nov 2018 New trial record